1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Generic Drug Opportunity Assessment : Boceprevir (Victrelis)

Generic Drug Opportunity Assessment : Boceprevir (Victrelis)

  • January 2014
  • -
  • Greystone Research Associates

Greystone Research Associates has identified a branded drug that represents an attractive opportunity for generic drug companies. Details of our findings are contained in an insightful assessment.

The Brand

Boceprevir is a direct acting antiviral drug against the hepatitis C (HCV) virus It is an inhibitor (protease inhibitor) of the HCV non-structural protein 3 (NS3) serine protease. Protease inhibitors are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis caused by hepatitis C virus. Protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Boceprevir (Victrelis) and the competing telaprevir (Incivek, Vertex Parmaceuticals) are indicated in combination with peginterferon plus ribavirin for genotype-1 HCV infection, the main HCV genotype worldwide.

The Market

Hepatitis C virus (HCV) is transmitted mainly by blood-to-blood contact, although it may be transmitted through unsafe sex. An estimated 3.9 million (1.8%) in the U.S. have been infected with HCV, of whom 2.7 million are chronically infected. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year.

Competitive Landscape

Incivek (telaprevir) is supplied by Vertex Pharmaceuticals. Incivek is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that is prescribed in combination with pegylated-interferon, or peg-IFN, and ribavirin, or RBV. Incivek was approved by the FDA, in the second quarter of 2011 and by Health Canada in the third quarter of 2011.
Incivek (telaprevir) is supplied by Vertex Pharmaceuticals. Incivek is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that is prescribed in combination with pegylated-interferon, or peg-IFN, and ribavirin, or RBV. Incivek was approved by the FDA, in the second quarter of 2011 and by Health Canada in the third quarter of 2011. In the third quarter of 2011, Vertex marketing partners Janssen Pharmaceutica, N.V., Mitsubishi Tanabe Pharma obtained marketing approval for telaprevir from the European Commission and the Japanese Ministry of Health, Labor and Welfare, respectively. Janssen markets telaprevir under the brand name INCIVO in Europe and other countries in its territories, and Mitsubishi Tanabe markets telaprevir under the brand name Telavic in Japan.

ANDA P (IV) Certification Activity

The antivirals segment has been one of the more active in recent years in terms of ANDA P 4 filings. There have been thirteen P (IV) patent certifications filed against branded antiviral drugs in the past three years.

The Opportunity

Competition among antivirals is quite high due to the number of alternative therapeutic drugs available and also because of the generally low level of specificity for any given drug in the treatment of a particular viral condition. As a result ANDA first-filers typically have a narrow window in which to work to produce the revenue numbers in their forecasts. In this environment, pre-launch planning and secondary sources of supply for critical materials can be critical to the success of the filing.

Generic Revenue Opportunity

We are predicting that the ANDA first-filer entering the market in will capture of the total global market for boceprevir drugs for the treatment of HCV in calendar year . The majority of sales will come during the 180-day exclusivity period, at a price approximately of the brand price.

Report Highlights

Victrelis – The Brand
Boceprevir – The Product
Boceprevir – The Market
Boceprevir – The Opportunity
Manufacturing and Sourcing
Victrelis Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic First-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Table Of Contents

Generic Drug Opportunity Assessment : Boceprevir (Victrelis)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

In this report, Persistence Market Research (PMR) offers an eight year forecast of the global hepatitis C treatment market between 2016 and 2024. The current study reveals the market trends and market ...

Liver Fibrosis Global Clinical Trials Review, H2, 2016

Liver Fibrosis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Liver Fibrosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical ...

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Hepatitis C

May 2016 $ 5000

Download Unlimited Documents from Trusted Public Sources

Hepatitis Treatment and Anti-Infective Market in India

  • February 2017
    2 pages
  • Hepatitis Treat...  

    Anti-Infective  

    Antiviral  

  • India  

View report >

Hepatitis Treatment Market in Japan - Forecast

  • January 2017
    7 pages
  • Hepatitis Treat...  

    Oligonucleotide  

  • Japan  

View report >

Hepatitis Treatment Market in the US

  • January 2017
    19 pages
  • Hepatitis Treat...  

    Antiviral  

    Therapy  

  • United States  

View report >

Related Market Segments :

Hepatitis Treatment
Antiviral
Hepatitis

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.